Determinants of left ventricular mass in children with autosomal recessive polycystic kidney disease
- PMID: 41053527
- DOI: 10.1007/s40620-025-02426-y
Determinants of left ventricular mass in children with autosomal recessive polycystic kidney disease
Abstract
Background: Hypertension and left ventricular (LV) hypertrophy (LVH) are common in autosomal recessive polycystic kidney disease (ARPKD). We examined clinical determinants of LV mass in children with ARPKD.
Methods: Retrospective study of patients with ARPKD with available echocardiogram data. Casual blood pressure (BP) percentiles, 24-h ambulatory BP monitor (ABPM) parameters, antihypertensive medications, and estimated glomerular filtration rate (eGFR) within 6 months of echocardiogram were collected. Outcomes included LV mass Z-score, LV mass index [LVMI in g/m2.7 and g/(m2.16 + 0.09)], and LVH.
Results: Thirty patients with ARPKD (median age 7.2 years [IQR 3.4, 12.8]) had echocardiograms, 28 had casual BPs, 11 had ABPMs, and 93% were on antihypertensives. LVH occurred in 23% based on LVMI in g/m2.7 > 95th percentile, and in 50% based on LVMI > 45 g/(m2.16 + 0.09). Younger age correlated with higher number of antihypertensives (ρ = - 0.46, P = 0.014) and higher casual systolic and diastolic BP percentiles (r = - 0.74, P < 0.001; r = - 0.81, P < 0.001). After adjusting for age, sex, and eGFR, LV mass was not significantly associated with casual BP or ABPM, except for a negative association between LV mass Z-score and casual diastolic BP percentile (β coefficient - 0.31, P = 0.04). After adjusting for age, sex, and casual BP, both LVMI [in g/m2.7 and g/(m2.16 + 0.09)] and LV mass Z-score were significantly negatively associated with eGFR (β -1.08, P = 0.003; β -0.79, P = 0.007; and β -0.07, P = 0.01, respectively).
Conclusions: Young children with ARPKD have a higher burden of hypertension. LV mass was unexpectedly not significantly associated with BP but was negatively associated with eGFR.
Keywords: Ambulatory blood pressure monitoring; Autosomal recessive polycystic kidney disease; Hypertension; Left ventricular hypertrophy; Left ventricular mass.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interests: The authors have no relevant financial or non-financial interests to disclose. Ethical approval: The study was determined by the CHOP Institutional Review Board (IRB 21–018989) to meet exemption criteria per Title 45 of the U.S. Code of Federal Regulations §46.104(d) 4(iii). A waiver of HIPAA authorization/consent was granted by the CHOP Institutional Review Board (IRB 21–018989). Consent for publication: A waiver of HIPAA authorization/consent was granted by the CHOP Institutional Review Board (IRB 21–018989).
References
-
- Alzarka B, Morizono H, Bollman JW et al (2017) Design and implementation of the Hepatorenal Fibrocystic Disease Core Center clinical database: a centralized resource for characterizing autosomal recessive polycystic kidney disease and other hepatorenal fibrocystic diseases. Front Pediatr 5:80. https://doi.org/10.3389/fped.2017.00080 - DOI - PubMed - PMC
-
- Nagasawa Y, Matthiesen S, Onuchic LF et al (2002) Identification and characterization of Pkhd1, the mouse orthologue of the human ARPKD gene. J Am Soc Nephrol 13:2246–2258. https://doi.org/10.1097/01.ASN.0000030392.19694.9D - DOI - PubMed
-
- Menezes LFC, Cai Y, Nagasawa Y et al (2004) Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. Kidney Int 66:1345–1355. https://doi.org/10.1111/j.1523-1755.2004.00844.x - DOI - PubMed
-
- Adeva M, El-Youssef M, Rossetti S et al (2006) Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine 85:1–21. https://doi.org/10.1097/01.md.0000200165.90373.9a - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous